Halozyme Therapeutics, Inc. Aktie News

The medical technology stock is in a consolidation pattern and testing a key level. The biotech had a beat-and-raise quarter.

Royalty revenue contribution expected to begin as early as 2030 Initial partner targets include derisked MoAs that are approved blockbusters today Highly scalable licensing model and long duration IP into 2040s; potential for individual product IP extension through proprietary reformulation Two of Elektrofi's partners projected to begin Hypercon™ formulated product clinical development by year ...

Some of these companies are firing on all cylinders and trading at lofty valuations. Others face short-term challenges that have them looking like "buy the dip" opportunities.

SAN DIEGO and UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Nov. 17, 2025 /PRNewswire/ -- Merus N.V.

DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology SAN DIEGO , Nov. 7, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson received U.S. Food and Drug Administration (FDA) approval of a new indication for DARZALEX Faspro® (daratumumab and hyaluronidase-fihj) co-formulated with ENHANZE®, as single agen...

SAN DIEGO , Nov. 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), today announced the pricing of $650 million aggregate principal amount of 0% convertible senior notes due 2031 (the "2031 Notes") and $650 million aggregate principal amount of 0.875% convertible senior notes due 2032 (the "2032 Notes" and, together with the 2031 Notes, the "Conver...

Renaissance Group acquired 478,735 shares of Halozyme Therapeutics; estimated $35.11 million trade based on quarterly average pricing. Transaction represents 1.32% of reported U.S. equity assets under management as of September 30, 2025.

SAN DIEGO , Nov. 5, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), today announced that it intends to offer, subject to market conditions and other factors, $650 million aggregate principal amount of convertible senior notes due 2031 (the "2031 Notes") and $650 million aggregate principal amount of convertible senior notes due 2032 (the "2032 Note...